65,437 trials
Soft Tissue Sarcoma
Primary: Change in Total T-cell Level in Tumour Tissues From Baseline (Step 1, Week 1, Day 1) to End of Step 1 (Step 1, Week 3-5) — 1.9 factor change in cells/mm2
Myeloma
Primary: Time From Transplant to Neutrophil Count Recovery — 12; 12 days — p=0.89
Unresectable Hepatocellular Carcinoma
Primary: Overall Survival (OS) Results Are Based on the Modified Intent-to-treat (mITT) — 200; 206 Participants — p=0.4552
Type 1 Diabetes
Primary: Immunoglobulin G (IgG) Antibodies — 270.0 mcg/mL
Contact Lens
Primary: Subjective Assessment of Precision1® Daily Disposable Contact Lens — 6.5 units on a scale
Relapsed or Refractory Multiple Myeloma
Primary: Overall Response Rate (ORR) As Assessed by the Independent Review Committee (IRC) — 57.7 percentage of participants
Hypertension, Pulmonary
Primary: Change From Baseline in Depressive Symptoms on the 27-point Patient Health Questionnaire-9 Scales (PHQ-9) to Week #8. — 3.44444; 7.6666 score on scale — p=< 0.054
Healthy
Primary: Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-t) of Tepotinib — 15348; 16523 Hours*nanogram per milliliter…
Covid19
Primary: Percentage Change in Testing During the Study Compared to Tests Completed Prior to Study Start — 0.0965; 0.0128 Percent change
Atrial Fibrillation Paroxysmal
Primary: Change in Atrial Fibrillation Effect on QualiTy of Life Survey (AFEQT) — 1.7; 0.5 units on a scale
Postoperative Pain · Postoperative Delirium
Primary: Postoperative Pain After Cardiac Surgery — 2.28; 2.17 units on a scale
Graft-versus-host Disease
Primary: Percentage of Participants With Grade II-IV Acute GvHD by Day +120 — 17.4 Percentage of participants
Huntingtons Disease
Primary: Change From Baseline in the Composite Unified Huntington's Disease Rating Scale (cUHDRS) Score-Z Score — 0.103; -0.367; -0.139; -1.173 Scores on a Scale
Non-Hodgkin Lymphoma
Primary: Overall Response Rate (ORR) — 6; 2; 2; 0 Participants
Peritoneal Carcinomatosis · Ovarian Cancer Stage IIIB · Ovarian Cancer Stage IIIC
Primary: Maximally Tolerated Dose (MTD) of Abraxane — 0; 0; 0; 0 Participants